You are about to leave a GSK website. By clicking this link, you will be taken to a website that is independent from GSK. The site you are linking to is not controlled or endorsed by GSK, and GSK is not responsible for the content provided on that site.

Skip to main content

Timeout

You are using an unsupported browser.

Some features of this site may not function properly. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge.

  • NUCALA Also Treats
    • Severe Asthma
    • CRSwNP
    • EGPA
    • HES
  • For US residents only
  • Prescribing Information
  • Patient Information
  • Visit US Healthcare Professionals Site
Visit Nucala mepolizumab homepage

Sign up for

mynucala-logo.svg

A network of services for those beginning or continuing treatment with NUCALA.

Your MyNUCALA Support team can help guide you through costs, questions about NUCALA, and more.

And as you start, you’ll have access to your MyNUCALA Nurse Support* team to get you on your way.

*MyNUCALA personnel do not give medical advice, and will direct you to your healthcare provider for any disease-, treatment-, or referral-related questions. 

MyNUCALA Nurse Support team

Ready to sign up? 

Icon: Email

MyNUCALA will keep in touch!

We’ll help provide support, resources, and reminders to keep your treatment plan on track. Just fill out the short form below.

Get on your way with MyNUCALA. 

MyNUCALA logo
Icon: Messages

Still have questions? MyNUCALA Nurse support* is here.

844-4-NUCALA (844-468-2252)

Monday – Friday, 8 AM – 8 PM ET. Healthcare professionals* are available to help answer questions about NUCALA.

*MyNUCALA personnel do not give medical advice, and will direct you to your healthcare provider for any disease-, treatment-, or referral-related questions. 

Approved Uses & Safety Info
Approved Uses

NUCALA is a prescription medicine for the:

  • add-on maintenance treatment of patients 6 and older with severe eosinophilic asthma. NUCALA is not used to treat sudden breathing problems.
  • add-on maintenance treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adults whose disease is not controlled with nasal corticosteroids.
  • treatment of adults with eosinophilic granulomatosis with polyangiitis (EGPA).
  • treatment of people 12 years of age and older with hypereosinophilic syndrome (HES).

NUCALA is a prescription medicine for the:

  • add-on maintenance treatment of patients 6 and older with severe eosinophilic asthma. NUCALA is not used to treat sudden breathing problems.
  • add-on maintenance treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adults whose disease is not controlled with nasal corticosteroids.
  • treatment of adults with eosinophilic granulomatosis with polyangiitis (EGPA).
  • treatment of people 12 years of age and older with hypereosinophilic syndrome (HES).

NUCALA is a prescription medicine for the:

  • add-on maintenance treatment of patients 6 and older with severe eosinophilic asthma. NUCALA is not used to treat sudden breathing problems.
  • add-on maintenance treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adults whose disease is not controlled with nasal corticosteroids.
  • treatment of adults with eosinophilic granulomatosis with polyangiitis (EGPA).
  • treatment of people 12 years of age and older with hypereosinophilic syndrome (HES).
Important Safety Information

Do not use NUCALA if you are allergic to mepolizumab or any of the ingredients in NUCALA.

Do not use NUCALA if you are allergic to mepolizumab or any of the ingredients in NUCALA.

Do not use NUCALA if you are allergic to mepolizumab or any of the ingredients in NUCALA.

Do not use to treat sudden breathing problems.

NUCALA can cause serious side effects, including:

  • allergic (hypersensitivity) reactions, including anaphylaxis. Serious allergic reactions can happen after you get your NUCALA injection. Allergic reactions can sometimes happen hours or days after you get a dose of NUCALA. Tell your healthcare provider or get emergency help right away if you have any of the following symptoms of an allergic reaction:
    • swelling of your face, mouth, and tongue
    • breathing problems
    • fainting, dizziness, feeling lightheaded (low blood pressure)
    • rash
    • hives
  • Herpes zoster infections that can cause shingles have happened in people who received NUCALA.

Before receiving NUCALA, tell your healthcare provider about all of your medical conditions, including if you:

  • are taking oral or inhaled corticosteroid medicines. Do not stop taking your other medicines, including your corticosteroid medicines, unless instructed by your healthcare provider because this may cause other symptoms to come back.
  • have a parasitic (helminth) infection.
  • are pregnant or plan to become pregnant. It is not known if NUCALA may harm your unborn baby.
  • are breastfeeding or plan to breastfeed. You and your healthcare provider should decide if you will use NUCALA and breastfeed. You should not do both without talking with your healthcare provider first.
  • are taking prescription and over-the-counter medicines, vitamins, and herbal supplements.

The most common side effects of NUCALA include: headache, injection site reactions (pain, redness, swelling, itching, or a burning feeling at the injection site), back pain, and tiredness (fatigue). Mouth/throat pain and joint pain have been reported with CRSwNP.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088

Follow Us:

Visit GSK Contact Us website
Visit Gateway to Nucala page

If you don’t have prescription coverage and need help paying for your medicines, call us at 1-844-4-NUCALA (1-844-468-2252).

  • Legal Notice
  • Privacy Notice
  • Consumer Health Privacy
  • Interest-based Ads
  • Medicine Savings
  • Contact Us
  • Unsubscribe
This is my caption
Back to Top

Trademarks are owned by or licensed to the GSK group of companies.

Visit GSK US website

This website is funded and developed by GSK.
This site is intended for US residents only.
©2023 GSK or licensor.
MPLWCNT220055 July 2022
Produced in USA.